Wellgistics Health provided a corporate outlook for 2026 to stakeholders, focusing on integrating their EinsteinRx™ AI platform into pharmacy client point of sale systems.
The company aims to onboard up to 500 pharmacies per month into the Wellgistics Pharmacy Network by the end of 2026.
Expansion efforts include developing relationships in diabetes, weight loss, cardiometabolic, and Long COVID patient markets.
Integration of EinsteinRx™
Efforts are underway to integrate the AI platform into pharmacy client systems, aiming to streamline processes and reduce friction.
Pharmacy Network Growth
The goal is to onboard 500 pharmacies per month by the end of 2026, enhancing the Wellgistics Pharmacy Network.
Manufacturer Relationships
Focus on expanding relationships in diabetes, weight loss, cardiometabolic, and Long COVID patient markets.
PharmacyChain™ Development
Assessment ongoing for blockchain-enabled healthcare smart contract development, aimed at improving efficiency in healthcare delivery.
Market Insights
Insights on the US diabetes, GLP-1 agonist, and cardiometabolic disorders markets, highlighting growth opportunities and patient impact.
- Efforts are focused on optimizing the onboarding process for pharmacy clients and accelerating the pharmacy conversion marketing.
- Expansion into various patient markets is expected to enhance the range of services provided by the Wellgistics Pharmacy Network.
- Development of PharmacyChain™ aims to improve healthcare delivery efficiency, increase transparency, and reduce administrative burdens in the system.
Wellgistics Health's 2026 outlook emphasizes innovation and growth in pharmacy network integration, patient markets, and smart contract development. The company's strategic focus on technology integration and market expansion positions it for significant advancement in the healthcare sector.